EP1061806A4 - Producer cells for replication selective viruses in the treatment of malignancy - Google Patents

Producer cells for replication selective viruses in the treatment of malignancy

Info

Publication number
EP1061806A4
EP1061806A4 EP99911363A EP99911363A EP1061806A4 EP 1061806 A4 EP1061806 A4 EP 1061806A4 EP 99911363 A EP99911363 A EP 99911363A EP 99911363 A EP99911363 A EP 99911363A EP 1061806 A4 EP1061806 A4 EP 1061806A4
Authority
EP
European Patent Office
Prior art keywords
malignancy
treatment
producer cells
replication selective
selective viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99911363A
Other languages
German (de)
French (fr)
Other versions
EP1061806A1 (en
Inventor
Katherine L Molnar-Kimber
David J Caparrelli
Larry R Kaiser
Steven M Albelda
George Coukos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP1061806A1 publication Critical patent/EP1061806A1/en
Publication of EP1061806A4 publication Critical patent/EP1061806A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
EP99911363A 1998-03-12 1999-03-12 Producer cells for replication selective viruses in the treatment of malignancy Withdrawn EP1061806A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7768198P 1998-03-12 1998-03-12
US77681P 1998-03-12
PCT/US1999/005466 WO1999045783A1 (en) 1998-03-12 1999-03-12 Producer cells for replication selective viruses in the treatment of malignancy

Publications (2)

Publication Number Publication Date
EP1061806A1 EP1061806A1 (en) 2000-12-27
EP1061806A4 true EP1061806A4 (en) 2001-09-12

Family

ID=22139477

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99911363A Withdrawn EP1061806A4 (en) 1998-03-12 1999-03-12 Producer cells for replication selective viruses in the treatment of malignancy

Country Status (4)

Country Link
EP (1) EP1061806A4 (en)
AU (1) AU3001799A (en)
CA (1) CA2323067A1 (en)
WO (1) WO1999045783A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
NZ550861A (en) 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
CN1289098C (en) * 1999-09-17 2006-12-13 威尔斯塔生物公司 Vesicular stromatitis virus (VSV)
WO2001035970A1 (en) 1999-11-12 2001-05-25 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
BRPI0107736B8 (en) * 2000-01-21 2021-05-25 Biovex Ltd hsv1 js1 strain, pharmaceutical composition, and use of an hsv1 js1 strain
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (en) 2000-05-03 2003-04-23 Oncolytics Biotech Inc REMOVAL OF REOVIRUS FROM NEOPLASTIC CELLS INTERMEDIATE BY RAS FROM MIXED CELL COMPOSITIONS
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
CA2430495A1 (en) * 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
MXPA03010278A (en) * 2001-05-11 2004-12-06 Wellstat Biologics Corp Oncolytic virus therapy.
US20050169889A1 (en) * 2002-04-26 2005-08-04 Wellstat Biologics Corporation Immunogenic agent therapy using plasmapheresis or exchange transfusion
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20070134202A1 (en) * 2003-10-15 2007-06-14 The New Industry Reserch Organization Cancer gene therapeutic drug
US20070077231A1 (en) 2005-09-30 2007-04-05 Contag Christopher H Immune effector cells pre-infected with oncolytic virus
WO2008009115A1 (en) * 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
JP6462361B2 (en) 2011-11-17 2019-01-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ Methods and techniques for collecting, reporting and managing information about medical diagnostic procedures
JP6358831B2 (en) * 2014-03-31 2018-07-18 雄行 濱田 Novel cell, inducer of antitumor effect using the same, drug for cancer gene therapy, and method of inducing antitumor effect
CN104958324A (en) 2015-05-29 2015-10-07 黄波 Oncolytic virus preparation and preparing method thereof
EP3649648A1 (en) 2017-07-07 2020-05-13 Bayer Healthcare LLC System, method, and computer program product for peer exchange of data between injection systems
SG11202005934WA (en) * 2017-12-29 2020-07-29 Genemedicine Co Ltd Cell sheet for gene delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009654A1 (en) * 1993-10-01 1995-04-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gene therapy of the nervous system
WO1997026904A1 (en) * 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509578A (en) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター Cancer treatment using malignant cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009654A1 (en) * 1993-10-01 1995-04-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gene therapy of the nervous system
WO1997026904A1 (en) * 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COUKOS G ET AL: "Producer cells enhance the oncolytic effect of a replication-competent ICP34.5-null herpes simplex virus-1 (HSV-1) strain in epithelial ovarian cancer.", CANCER GENE THERAPY, vol. 5, no. 6 CONF. SUPPL., November 1998 (1998-11-01), Seventh International Conference on Gene Therapy of Cancer;San Diego, California, USA; November 19-21, 1998, pages S7, XP000993223, ISSN: 0929-1903 *
FREEMAN S ET AL: "the treatment of ovarian cancer with a gene modified cancer vaccine : a phase I study", HUMAN GENE THERAPY, vol. 6, no. 7, July 1995 (1995-07-01), pages 927 - 939, XP000993236 *
See also references of WO9945783A1 *
TAMIYA T ET AL: "Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells.", GENE THERAPY, vol. 2, no. 8, 1995, pages 531 - 538, XP000993316, ISSN: 0969-7128 *
TUNG FRANK Y T ET AL: "Retroviral producer cells cause sarcoma in severe combined immunodeficiency mice.", JOURNAL OF BIOMEDICAL SCIENCE, vol. 2, no. 2, 1995, pages 131 - 135, XP000993275, ISSN: 1021-7770 *

Also Published As

Publication number Publication date
AU3001799A (en) 1999-09-27
WO1999045783A1 (en) 1999-09-16
EP1061806A1 (en) 2000-12-27
CA2323067A1 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
EP1061806A4 (en) Producer cells for replication selective viruses in the treatment of malignancy
HUP9900163A2 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
GB2337200B (en) Smoking substance for use in therapy
EP1035150A4 (en) Copolycarbonate and process for producing the same
GB9800942D0 (en) Well treatment
EP0671768A3 (en) Improvements in or relating to electrodes for LSI.
MXPA01011923A (en) Compositions and methods for treating cell proliferation disorders.
HK1034216A1 (en) Fluid energy milling process and apparatus.
GB9816234D0 (en) Compounds for use in the treatment of inflammation
HK1075417A1 (en) Renal cell carcinoma treatment
AU2482400A (en) Advanced treatment for produced water
HUP0104568A3 (en) Human prostatic cell lines for cancer treatment
GB2314942B (en) Photomask for use in semiconductor manufacture
HUP0101947A3 (en) Combination for the treatment of tumors
GB2339576B (en) Biomass treatment
GB9912851D0 (en) Treating cells
IL139912A0 (en) Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals
EP1016682A4 (en) Tetracyclododecene compositions and process for producing the same
EP1081159A4 (en) Purified human activin and process for producing the same
ZA991786B (en) Therapeutic treatment for asthma.
GB9804572D0 (en) Improvements in pipes
GB9802388D0 (en) Waste water treatment,media therefor and its manufacture
EP1066272A4 (en) Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
GB9815497D0 (en) Treatment
GB9818524D0 (en) Inorgasmia treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001011

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010731

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 63/00 A, 7C 12N 1/20 B, 7C 12N 15/00 B, 7C 12P 21/06 B, 7A 61K 35/76 B, 7A 61K 48/00 B

17Q First examination report despatched

Effective date: 20021128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030409